{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:50:27Z","timestamp":1786985427103,"version":"build-2736575974"},"reference-count":24,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81202573"],"award-info":[{"award-number":["81202573"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81773745"],"award-info":[{"award-number":["81773745"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Suzhou Science & Technology Foundation","award":["SYS201665"],"award-info":[{"award-number":["SYS201665"]}]},{"DOI":"10.13039\/501100012246","name":"PAPD","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100012246","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1016\/j.bmc.2018.02.013","type":"journal-article","created":{"date-parts":[[2018,2,12]],"date-time":"2018-02-12T13:00:51Z","timestamp":1518440451000},"page":"1653-1664","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"title":["Development of benzoxazole deoxybenzoin oxime and acyloxylamine derivatives targeting innate immune sensors and xanthine oxidase for treatment of gout"],"prefix":"10.1016","volume":"26","author":[{"given":"Jun","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zehao","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengze","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingxing","family":"Miao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1487-6893","authenticated-orcid":false,"given":"Huanqiu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinghua","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmc.2018.02.013_b0005","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1097\/BOR.0000000000000367","article-title":"Major unanswered questions in the clinical gout field","volume":"29","author":"Stamp","year":"2017","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.bmc.2018.02.013_b0010","article-title":"Recent pharmacological advances in the management of gout","volume":"14","author":"Davies","year":"2017","journal-title":"Rheumatology"},{"key":"10.1016\/j.bmc.2018.02.013_b0015","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3899\/jrheum.140458","article-title":"The efficacy and safety of treatments for acute gout: results from a series of systematic literature reviews including Cochrane reviews on intraarticular glucocorticoids, colchicine, nonsteroidal antiinflammatory drugs, and interleukin-1 inhibitors","volume":"92","author":"Wechalekar","year":"2014","journal-title":"J Rheumatol Suppl"},{"key":"10.1016\/j.bmc.2018.02.013_b0020","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1097\/BOR.0000000000000143","article-title":"Interleukin-1 as a therapeutic target in gout","volume":"27","author":"Dumusc","year":"2015","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.bmc.2018.02.013_b0025","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1097\/BOR.0000000000000366","article-title":"Factors modulating the inflammatory response in acute gouty arthritis","volume":"29","author":"Cleophas","year":"2017","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.bmc.2018.02.013_b0030","first-page":"39","article-title":"The role of the NLRP3 inflammasome in gout","volume":"4","author":"Kingsbury","year":"2011","journal-title":"J Inflamm Res"},{"key":"10.1016\/j.bmc.2018.02.013_b0035","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s00296-013-2856-3","article-title":"Changes in toll-like receptor (TLR)4-NF\u03baB-IL1\u03b2 signaling in male gout patients might be involved in the pathogenesis of primary gouty arthritis","volume":"34","author":"Qing","year":"2014","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.bmc.2018.02.013_b0040","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.jep.2015.04.011","article-title":"Wuling San protects kidney dysfunction by inhibiting renal TLR4\/MyD88 signaling and NLRP3 inflammasome activation in high fructose-induced hyperuricemic mice","volume":"169","author":"Yang","year":"2017","journal-title":"J Ethnopharmacol"},{"key":"10.1016\/j.bmc.2018.02.013_b0045","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.biopha.2017.10.051","article-title":"Emodinol ameliorates urate nephropathy by regulating renal organic ion transporters and inhibiting immune inflammatory responses in rats","volume":"96","author":"Wu","year":"2017","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.bmc.2018.02.013_b0050","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1080\/14656566.2017.1351945","article-title":"Current and future therapies for gout","volume":"18","author":"Pascart","year":"2017","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.bmc.2018.02.013_b0055","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.12659\/MSM.899852","article-title":"Hyperuricemia-related diseases and xanthine oxidoreductase (XOR) inhibitors: an overview","volume":"22","author":"Chen","year":"2017","journal-title":"Med Sci Monit"},{"key":"10.1016\/j.bmc.2018.02.013_b0060","first-page":"125","article-title":"Use of newly available febuxostat in a case of chronic tophaceous gout contraindicated to allopurinol and probenecid","volume":"67","author":"Hilmi","year":"2012","journal-title":"Med J Malaysia"},{"key":"10.1016\/j.bmc.2018.02.013_b0065","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1177\/1759720X16646703","article-title":"Treatment of hyperuricemia in gout: current therapeutic options, latest developments and clinical implications","volume":"8","author":"Sattui","year":"2016","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"10.1016\/j.bmc.2018.02.013_b0070","article-title":"Quercetin inhibits gout arthritis in mice.inductionof an opioid-dependent regulation of inflammasome","volume":"15","author":"Ruiz-Miyazawa","year":"2017","journal-title":"Inflammopharmacology"},{"key":"10.1016\/j.bmc.2018.02.013_b0075","first-page":"116","article-title":"A dietary bioflavonol suppresses monosodium urate crystal-induced inflammation in an animal model of acute gouty arthritis with reference to NLRP3 inflammasome, hypo-xanthine phospho-ribosyl transferase, and inflammatory mediators","volume":"768","author":"Dhanasekar","year":"2017","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.bmc.2018.02.013_b0080","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1189\/jlb.3A0114-005RR","article-title":"Isoliquiritigenin is a potent inhibitor of NLRP3 inflammasome activation and diet-induced adipose tissue inflammation","volume":"96","author":"Honda","year":"2014","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.bmc.2018.02.013_b0085","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1016\/j.phytochem.2010.07.008","article-title":"Suppression of homodimerization of toll-like receptor 4 by isoliquiritigenin","volume":"71","author":"Park","year":"2010","journal-title":"Phytochemistry"},{"key":"10.1016\/j.bmc.2018.02.013_b0090","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1002\/cmdc.201000107","article-title":"Design, synthesis, and immunosuppressive activity of new deoxybenzoin derivatives","volume":"5","author":"Li","year":"2010","journal-title":"Chem Med Chem"},{"key":"10.1016\/j.bmc.2018.02.013_b0095","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.biopha.2016.12.002","article-title":"(E)-2-(4-bromophenyl)-1-(2, 4-dihydroxyphenyl)ethanone oxime is a potential therapeutic agent for treatment of hyperuricemia through its dual inhibitory effects on XOD and URAT1","volume":"86","author":"Hu","year":"2017","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.bmc.2018.02.013_b0100","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.bmc.2016.10.022","article-title":"Discovery of novel curcumin derivatives targeting xanthine oxidase and urate transporter 1 as anti-hyperuricemic agents","volume":"25","author":"Ao","year":"2017","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.bmc.2018.02.013_b0105","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1093\/clinchem\/17.3.158","article-title":"A simplified alkaline phosphotungstate assay for uric acid in serum","volume":"17","author":"Carroll","year":"1971","journal-title":"Clin Chem"},{"key":"10.1016\/j.bmc.2018.02.013_b0110","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.ejmech.2017.03.002","article-title":"Synthesis, screening and docking of fused pyrano[3,2-d]pyrimidine derivatives as xanthine oxidase inhibitor","volume":"131","author":"Kaur","year":"2017","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2018.02.013_b0115","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1038\/nprot.2012.085","article-title":"Template-based protein structure modeling using the RaptorX web server","volume":"7","author":"K\u00e4llberg","year":"2012","journal-title":"Nat Protoc"},{"key":"10.1016\/j.bmc.2018.02.013_b0120","unstructured":"Glide, Schr\u00f6dinger, LLC, New York, NY, 2015."}],"container-title":["Bioorganic & Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089618301561?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089618301561?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T00:57:49Z","timestamp":1760835469000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0968089618301561"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5]]},"references-count":24,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["S0968089618301561"],"URL":"https:\/\/doi.org\/10.1016\/j.bmc.2018.02.013","relation":{},"ISSN":["0968-0896"],"issn-type":[{"value":"0968-0896","type":"print"}],"subject":[],"published":{"date-parts":[[2018,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development of benzoxazole deoxybenzoin oxime and acyloxylamine derivatives targeting innate immune sensors and xanthine oxidase for treatment of gout","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmc.2018.02.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}